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Background: Thromboelastography® (TEG) utilizes kaolin, an intrinsic pathway activator, to assess clotting function.
Recent published studies suggest that TEG results are commonly normal in patients receiving warfarin, despite an
increased International Normalized Ratio (INR). Because RapidTEG™ includes tissue factor, an extrinsic pathway
activator, as well as kaolin, we hypothesized that RapidTEG would be more sensitive in detecting a warfarin-effect.
Methods: Included in this prospective study were 22 consecutive patients undergoing elective cardioversion and
receiving warfarin. Prior to cardioversion, blood was collected to assess INR, Prothrombin Time, TEG, and RapidTEG.
Results: INR Results: 2.8 ± 0.5 (1.6 to 4.2). Prothrombin Time Results: 19.1 ± 2.2 (13.9. to 24.3).
TEG Results (Reference Range): R-Time: 8.3 ± 2.7 (2–8); K-Time: 2.1 ± 1.4 (1–3); Angle: 62.5 ± 10.3 (55–78); MA:
63.2 ± 10.3 (51–69); G: 9.4 ± 3.5 (4.6-10.9); R-Time within normal range: 10 (45.5%) with INR 2.9 ± 0.3; Correlation
coefficients for INR and each of the 5 TEG variables were insignificant (P > 0.05).
RapidTEG Results (Reference Range): ACT: 132 ± 58 (86–118); K-Time: 1.2 ± 0.5 (1–2); Angle: 75.4 ± 5.2 (64–80);
MA: 63.4 ± 5.1 (52–71); G: 8.9 ± 2.0 (5.0-11.6); ACT within normal range: 9 (40.9%) with INR 2.7 ± 0.5; Correlation
coefficients for INR and each of the 5 RapidTEG variables were insignificant (P > 0.05).
Conclusions: TEG, using kaolin activation, and RapidTEG, with kaolin and tissue factor activation, were normal in
a substantial percent of warfarin patients, despite an increased INR. The false-negative rate for detecting warfarin
coagulopathy with either test is unacceptable. The lack of correlation between INR and all TEG and RapidTEG
components further indicates that these methodologies are insensitive to warfarin effects. Findings suggest that
intrinsic pathway activation may mitigate detection of an extrinsic pathway coagulopathy.
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The prevalence of warfarin use in the United States is
unknown, however the Food and Drug Administration
estimates that more than 31 million prescriptions for
warfarin were written in 2004 [1]. A publication by Dossett
indicates that warfarin use is common among injured
patients and its prevalence has increased each year since
2002 [2]. In that study, warfarin was found to be associated
with a significant increase in trauma-related mortality,
even after adjusting for confounding co-morbidities.* Correspondence: dunham.michael@sbcglobal.net
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unless otherwise stated.Thromboelastography (TEG®) assesses the viscoelastic
properties of blood during the clotting process [3-7].
The R-Time (clotting time) is the time in minutes from
clot activation until the graphic amplitude is 2 mm, that
is, until the first detectable levels of fibrin clot formation
[3,4,6,7]. It is important to recognize that with the TEG
assay, kaolin or celite, as factor XII activators, or tissue
factor may be used to enhance clot formation [3,7]. Sev-
eral review articles emphasized the importance of know-
ing the “assay variant” (clotting activator) utilized in a
given set of studies [4-6]. In other words, several differ-
ent reagents can be used: Kaolin – Intrinsic Activator;
Tissue Factor – Extrinsic Activator; and others [5,6].
Thus, depending on the activator, this may correspond
to clotting times measured by aPTT (intrinsic process)al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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an intrinsic activator; therefore coagulation time (R-Time)
is sensitive to heparin [4].
Recent literature suggests that viscoelastic study re-
sults vary, when there is a warfarin-effect, depending on
the activator being used. Of relevance, a study by Rumph
demonstrated that Thromboelastometry (ROTEM®), using
calcium chloride and tissue factor activation, showed
marked increases in Clotting Time (analogous to TEG R-
Time), when warfarin-treated plasma was analyzed [8].
Warfarin Clotting Time was 289 ± 78 seconds in the
warfarin-treated plasma, with a normal value of 38–79 sec-
onds. In contradistinction, a recently published study
demonstrated that kaolin-activated TEG results were typ-
ically normal in patients on warfarin and with a thera-
peutic International Normalized Ratio (INR) [9]. Of eight
patients taking warfarin and with therapeutic INR values,
only one patient had an abnormal TEG.
In an isolated case at our institution, a patient on war-
farin prior to hospital admission was admitted to the
surgical intensive care unit and found to have INR
values of five and 11 within 60 minutes of each other.
The patient had a large retroperitoneal hematoma by
CT scan, severe hypotension, and profound lactic acid-
osis. Two TEG Reaction (R)-Time values were within
the normal range at the same times that the INR values
were severely elevated. This compellingly suggested to
the first author that TEG, with kaolin activation, may be
insensitive to warfarin-effect. To investigate the sensitiv-
ity of kaolin-activated TEG to warfarin-effect, we evalu-
ated the Prothrombin Time (PT), INR, and TEG values in
patients on warfarin who were undergoing elective cardio-
version. Because the RapidTEG™ (rTEG) assay includes
tissue factor activation, in addition to kaolin, rTEG was
also performed. We hypothesized that TEG would be rela-
tively insensitive to warfarin-coagulopathy, whereas rTEG
would have improved and acceptable sensitivity.
Methods
This is a study of patients receiving Wafarin therapy
who were scheduled for elective cardioversion with pro-
spective laboratory evaluation of INR, PT, and standard
parameters of both TEG (kaolin activation) and rTEG
(kaolin and tissue factor activation). TEG parameters
assessed were R-Time, Kinetics (K)-Time, alpha-angle,
maximum amplitude (MA), and G-value. rTEG parame-
ters evaluated included Activated Clotting Time (ACT [R-
Time derivative]), K-Time, alpha-angle, MA, and G-value.
When INR was > 1.5 and TEG R-Time was > 8.0, the
established upper limit of normal, TEG was considered to
have a true-positive response. When INR was > 1.5 and
TEG R-Time was ≤ 8.0, TEG was considered to have a
false-negative response. When INR was > 1.5 and ACT
was > 118, the established upper limit of normal, rTEGwas considered to have a true-positive response. When
INR was > 1.5 and ACT was ≤ 118, rTEG was considered
to have a false-negative response.
The St. Elizabeth Health Center Institutional Review
Board approved this study, with consent waiver, and in-
cluded patients who presented for elective cardioversion
at St. Elizabeth’s Health Center between July 27, 2012 and
October 9, 2012. Patients included in the study were those
greater than 18 years of age, who were receiving continu-
ous Wafarin therapy. Patients excluded from the study
were those who were taking other anticoagulant medica-
tions or platelet inhibitors such as Aspirin, Ticlopidine,
Clopidogrel, Abciximab, Tirofiban, and Eptifibatide, un-
fractionated or low-molecular-weight heparin, Dabigatran,
and Argatroban.
A 4.5 mL sample of whole blood was collected into a
buffered sodium citrate phlebotomy vial at the point of
care one-hour prior to cardioversion. The blood was
then transported to a College of American Pathologists
and Clinical Laboratory Improvement Amendments cer-
tified laboratory, where the samples were processed and
analyzed. Using manufacturer specified techniques, TEG
and rTEG analyses were performed on a Thromboelasto-
graph Whole Blood Coagulation Analyzer (Model 5000,
Haemoscope Corporation, Niles, Il, USA). Each speci-
men was maintained at room temperature for 15 minutes
after collection to equilibrate. Normal and abnormal
controls were run for TEG/rTEG and PT/INR per
manufacturer guidelines prior to testing patient samples.
Approximately 2 mL of citrated whole blood was run on
the TEG/rTEG analyzer per manufacturer instructions
by an American Society for Clinical Pathology certified
Medical Technologist. The remaining 2.5 mL of citrated
whole blood was centrifuged at 3,500 rpm for 10 minutes.
The plasma was then analyzed for PT and INR on an ACL
TOP® 500 Hemostasis Testing System (Instrumentation
Laboratories, Belgium) per manufacturer instructions by a
certified Medical Technologist. TEG/rTEG and PT/INR
were performed from the same citrated sample within one
hour of collection. No specimen was hemolyzed.
The results were entered into Microsoft Excel and
imported into SAS System for Windows, release 9.2
(SAS Institute Inc., Cary, NC, USA) to perform the stat-
istical analysis. P value of < 0.05 represented statistical
significance. Correlation coefficient analyses were per-
formed between the INR and each of the TEG and rTEG
parameter values. The sensitivity for detecting an ele-
vated INR was computed for each TEG and rTEG par-
ameter. Specifically, a rate was determined for each TEG
and rTEG parameter to determine if the values were
above the upper limit of the normal range, as reported
by the device manufacturer from healthy volunteers.
TEG and rTEG analysis kits were donated by the Hae-
moscope Corporation.
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During July 2012 through October, 2012, a total of 22
consecutive patients undergoing elective cardioversion
had an increased INR, due to warfarin. For the 22 patients,
INR was 2.8 ± 0.5 (1.6 to 4.2) and PT was 19.1 ± 2.2 (13.9.
to 24.3). TEG results with reference ranges are in Table 1.
TEG R-Time value was above the upper reference range
of 8.0 (true-positive) in 12/22, indicating that TEG sen-
sitivity for warfarin coagulopathy was 54.5% (95% CI:
34.5-73.1%). Accordingly, the false-negative rate (10/22) for
warfarin coagulopathy (INR 2.9 ± 0.3) was 45.5% (95% CI:
25.8-65.5%). P-values for INR and TEG correlations were
as follows: R-Time P = 0.7657, K-Time P = 0.8336, alpha-
angle P = 0.9783, MA P = 0.7057, G-value P = 0.9818.
RapidTEG results with reference ranges are in Table 1.
RapidTEG ACT-value was above the upper reference
range of 118 (true-positive) in 13/22, suggesting that
RapidTEG sensitivity for warfarin coagulopathy was 59.1%
(95% CI: 38.5-76.8%). Apropos, the false-negative rate
(9/22) for warfarin coagulopathy (INR 2.7 ± 0.5) was
40.9% (95% CI: 23.2-61.5%). P-values for INR and Rapid-
TEG correlations were as follows: ACT P = 0.7700, K-Time
P = 0.4710, alpha-angle P = 0.1167, MA P = 0.5682, G-value
P = 0.4554.
Discussion
Although patients in the current study had a substantial
warfarin-effect according to PT and INR values, the
kaolin-activated TEG R-Time values were within the
normal range in nearly half. The other TEG parameters
(K-Time, alpha-angle, MA, and G-value) were virtually
always within the normal range. Additionally, there were
no significant correlations between any of the five TEG
variables and the INR values. Contrary to our hypoth-
esis, the kaolin plus tissue factor activated rTEG results
revealed similar findings. Thus, we believe that TEG andTable 1 INR, TEG and rTEG results and reference ranges
Parameter Mean ± SD Reference range
INR 2.8 ± 0.5 < 1.5
TEG R-Time 8.3 ± 2.7 2-8
TEG K-Time 2.1 ± 1.4 1-3.0
TEG alpha-angle 62.5 ± 10.3 55-78
TEG MA 63.2 ± 10.3 51-69
TEG G-value 9.4 ± 3.5 4.6-10.9
rTEG ACT 132 ± 57.7 86-118
rTEG K-Time 1.2 ± 0.5 1-2.0
rTEG alpha-angle 75.4 ± 5.2 64-80.0
rTEG MA 63.4 ± 5.1 52-71.0
rTEG G-value 8.9 ± 2.0 5.0-11.6
INR, International Normalized Ration; TEG, Thromboelastography; rTEG,
RapidTEG; R-Time, Reaction Time; K-Time, Kinetics Time; MA, maximum
amplitude; G-value, clot strength/elasticity; ACT, activated clotting time.rTEG sensitivity for detecting a warfarin-effect is clinically
unacceptable. Because kaolin is common to TEG and
rTEG, it appears that intrinsic system activation is sub-
optimal for detecting alterations in the extrinsic system
warfarin produces.
Circumstances exist, in institutions with TEG-availability,
where simultaneous INR and TEG or RapidTEG testing
may occur. Alternatively, a TEG may be obtained, but an
INR test has not been recently performed. A clinician might
be influenced by the TEG result of a patient receiving
warfarin, if they believe that TEG provides an accurate
appraisal of warfarin-effect. In either circumstance, the
clinician needs to be aware of the relative insensitivity of
TEG and RapidTEG for assessing warfarin-coagulopathy.
Literature documenting insensitivity of TEG to warfarin
In addition to the current study, other investigators specif-
ically indicate that TEG is insensitive to warfarin-effects.
The Nascimento study found that only one of eight thera-
peutic warfarin-patients had an abnormal TEG [9]. In a
prospective study of patients given warfarin, the mean
TEG R-Time remained in the normal range [10]. Although
the number of TEG publications has nearly tripled in the
past five years, when compared to the previous five years,
there is a dearth of information regard its use for detecting
warfarin-effects. Apropos, there is no mention of warfarin
or Coumadin in five of six recent TEG-ROTEM review
articles [3-7]. However, Reikvam, in a recent TEG review
article, states “The method is not sensitive to Factor VII
deficiency and is not suitable for monitoring vitamin K
antagonist treatment” [11]. These findings appear to
represent a major knowledge deficiency in the under-
standing of viscoelastic hemostatic technologies for de-
tecting warfarin.
Nuances and intricacies of TEG
The literature includes five recent review articles that
describe nuances and intricacies regarding TEG meth-
odology, benefits, and limitations [3-7]. The reviews
describe a plethora of testing details and caveats ne-
cessary for proper testing and interpretation. A couple
of the TEG review articles have content that may leave
the superficial reader with false impressions. One arti-
cles states “The advantage of these techniques is that
they have the potential to measure the entire clotting
process, …….” [3]. A statement in another review also
appears to be an over generalization: “The trace is also
influenced by pharmacological agents such as antico-
agulants, antiplatelet therapy, and coagulation factor
supplementation” [6]. Although both manuscripts sub-
sequently provide appropriate caveats, a cursory per-
usal may leave the reader with a limited picture of
process details and an improper interpretation of the
results. In their reviews, Lang [4] and Chen [7] indicate
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aspects of hemostatic function.Conventional coagulation tests and viscoelastic
hemostatic analysis
Conventional coagulation tests (PT and activated partial
thromboplastin time) at best determine only the thrombin-
generation phase [4]. Further, these conventional coagula-
tion parameters are primarily intended to detect substances
acting on coagulation (vitamin K antagonists and un-
fractionated heparin)” [4]. In a recent clinical study of
trauma-induced coagulopathy using ROTEM, the cor-
relations between coagulation time in EXTEM/INTEM
and PT/aPTT were rather poor (r = 0.47-0.53) [5]. As
well, correlations for TEG R-Times with aPTT and PT
have been described as weak [5].Study limitations
A larger number of tested patients might have produced
slightly different sensitivity and false-negative rates, with
attendant 95% confidence intervals. The absence of pa-
tients with normal hemostatic function prohibited the
computation of TEG and rTEG specificity and accuracy
for warfarin-effect. Correlation coefficients between INR
and the TEG and rTEG parameter values may have been
different had persons with normal hemostatic function
been included. The performance of tissue factor-TEG as-
says, without kaolin, would have been elucidating.Conclusions
TEG, using kaolin activation, and rTEG, with kaolin and
tissue factor activation, were normal in a substantial per-
cent of warfarin patients, despite an increased INR. The
false-negative rate for detecting warfarin coagulopathy
with either test is clinically unacceptable. The lack of
correlation between INR and all TEG and rTEG com-
ponents further indicates that these methodologies are
insensitive to warfarin-effects. The study findings sug-
gest that intrinsic pathway activation may mitigate de-
tection of an extrinsic pathway coagulopathy. Current
investigation results will help to fill an apparent literature
void regarding warfarin-assessment during viscoelastic
hemostatic assessment. The investigation results are rele-
vant for the clinicians, hematologists, and pathologists,
when considering that TEG is commonly used by the
international medical community and that there are lit-
erally millions of patients receiving warfarin.
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